Neuburgh Advisers’s Solid Biosciences SLDB Stock Holding History

Neuburgh Advisers’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-76	Closed	-$31K	–	920
2018 Q4	$31K	Buy	+76	New	+$35.7K	﹤0.01%	848

Other funds holding SLDB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Neuburgh Advisers's SLDB Position: Q1 2019 in Review

Neuburgh Advisers sold out of Solid Biosciences (SLDB) in Q1 2019, closing a stake of 76 shares — an estimated $31K sold.

Neuburgh Advisers first reported a position in SLDB in Q4 2018 and held it in 1 quarter. The position peaked at $31K in Q4 2018. 74 funds tracked by Wall St. Rank hold SLDB as of Q1 2019.

Neuburgh Advisers reported no remaining Solid Biosciences position as of Q1 2019 after selling out during the quarter.
Neuburgh Advisers sold 76 Solid Biosciences shares in Q1 2019, an estimated $31K.
Neuburgh Advisers first reported a position in Solid Biosciences in Q4 2018 and held it in 1 quarter.
Neuburgh Advisers's Solid Biosciences position peaked at $31K in Q4 2018.
74 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2019.

Based on Neuburgh Advisers's 13F filing for Q1 2019, filed 13 May 2019.